| 368749 |
TLR4S100A9 |
HawkDock |
Completed |
2026-04-20 16:07:24 (UTC + 8 hours) |
| 368748 |
PDL1Atezolizumab_model5 |
MM/GBSA |
Completed |
2026-04-20 15:58:43 (UTC + 8 hours) |
| 368747 |
PDL1Atezolizumab_model4 |
MM/GBSA |
Completed |
2026-04-20 15:58:43 (UTC + 8 hours) |
| 368746 |
PDL1Atezolizumab_model3 |
MM/GBSA |
Completed |
2026-04-20 15:58:43 (UTC + 8 hours) |
| 368745 |
PDL1Atezolizumab_model2 |
MM/GBSA |
Completed |
2026-04-20 15:58:43 (UTC + 8 hours) |
| 368744 |
PDL1Atezolizumab_model1 |
MM/GBSA |
Completed |
2026-04-20 15:58:43 (UTC + 8 hours) |
| 368743 |
RPB4_OspC3 |
HawkDock |
Completed |
2026-04-20 15:52:04 (UTC + 8 hours) |
| 368742 |
PDL1Atezolizumab2 |
HawkDock |
Completed |
2026-04-20 15:48:31 (UTC + 8 hours) |
| 368741 |
DLATS100A9ABR |
HawkDock |
Completed |
2026-04-20 15:48:14 (UTC + 8 hours) |
| 368740 |
PDL1Atezolizumab2 |
HawkDock |
Completed |
2026-04-20 15:46:50 (UTC + 8 hours) |
| 368739 |
Trial |
MM/GBSA |
Completed |
2026-04-20 15:44:55 (UTC + 8 hours) |
| 368738 |
PDL1Atezolizumab |
HawkDock |
Completed |
2026-04-20 15:38:47 (UTC + 8 hours) |
| 368737 |
ab01_model10 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368736 |
ab01_model9 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368735 |
ab01_model8 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368734 |
ab01_model7 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368733 |
ab01_model6 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368732 |
ab01_model5 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368731 |
ab01_model4 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |
| 368730 |
ab01_model3 |
MM/GBSA |
Completed |
2026-04-20 15:35:05 (UTC + 8 hours) |